The rapidly changing landscape of gene therapies offers countless opportunities to create long lasting, single dose interventions that could replace current small molecule alternatives.

Currently most gene therapies are still too expensive a treatment option for most conditions, but that’s because the approval process is so expensive. In Próspera it makes a lot more fiscal sense to do phase-1 trials , for under $50,000 while still operating within established legal and ethical frameworks.

So far multiple companies have decided to sell the same 2 or 3 gene therapies in Próspera. They’re missing out on a vast number of available opportunities!

The following 100 entries represent opportunities across longevity, metabolic enhancement, peptide replacements, rare diseases, and monoclonal antibody alternatives. Each entry details the target condition, a rough gene therapy proposal, and the legacy biopharma market it disrupts.

All of these (surprisingly) have some form of animal validation, but some novel tweaks, delivery methods, etc., have been added here and there. More engineering and safety testing might make a few of these into gems, but there is always another way to tackle the same problem. The list, if anything, is meant to highlight market opportunities over specific methods.

I. Longevity, Cellular Rejuvenation & Metabolic Optimization

1. Gray Hair Reversal

Gene Therapy Proposal: Up-regulating the KITLG (Kit Ligand) / c-KIT and EDN3 / EDNRB (Endothelin receptor B) pathways via local gene delivery to force stem cells migration into the hair matrix. Will it cause hyper pigmentation?
Replaces & Revenue: Anti-aging hair market is $8.4 billion..

2. Systemic NAD+ Depletion

Gene Therapy Proposal: AAV-mediated liver delivery of Nicotinamide Phosphoribosyltransferase (NAMPT) to upregulate the rate-limiting enzyme in the NAD+ salvage pathway, restoring youthful cellular energetics and mitochondrial function.
Replaces & Revenue: Replaces daily oral NAD+ precursors (NR/NMN) and expensive weekly NAD+ IV infusions. The global longevity supplement market is valued at over $24 billion.

3. Epigenetic Aging & Cellular Senescence

Gene Therapy Proposal: An inducible minicircle vector delivering an optimized cassette of Yamanaka factors (OSK: Oct4, Sox2, Klf4) utilizing a doxycycline-regulated switch to safely reset cellular methylation age without inducing pluripotency or teratomas. Many are exploring this with their own twists. Maybe you have your own variation?
Replaces & Revenue: No direct clinical pharmaceutical equivalent exists; competes with boutique anti-aging wellness clinics and longevity therapeutic startups currently raising billions globally.

4. Visceral Adiposity & Metabolic Slowdown

Gene Therapy Proposal: Adipose-targeted delivery of a transgene encoding Uncoupling Protein 1 (UCP1) to transdifferentiate white adipose tissue into metabolically active brown adipose tissue, accelerating basal metabolic rate. Heat management and hyperthermia will be a hurdle here, requiring brilliant design of thermal feedback loop switching which will have applications well beyond obesity..
Replaces & Revenue: Replaces chronic GLP-1 agonist injections and surgical liposuction. The current anti-obesity medication market exceeds $36 billion and is climbing rapidly.

5. Inducible Mitophagy Acceleration Vector (IMAV)

Gene Therapy Proposal: Systemic delivery of a non-viral, transient minicircle vector encoding an optimized FUNDC1/Nix dual-expression cassette under a Doxycycline-inducible (Tet-On) promoter. This architecture restores cellular bioenergetic efficiency by aggressively clearing damaged, ROS-leaking mitochondria before they trigger the NLRP3 inflammasome, effectively reversing systemic inflammaging.
Replaces & Revenue: Replaces the need for daily, low-potency small-molecule mitochondrial support (like Urolithin A) and nonspecific antioxidant supplementation. The broader mitochondrial disease and longevity therapeutics market is rapidly expanding, with the mitochondrial-based therapeutics segment alone projected to reach over $1 billion by 2035.

6. Age-Related Thymic Involution

Gene Therapy Proposal: Localized delivery to the thymic remnant encoding Keratinocyte Growth Factor (KGF) or FOXN1 to stimulate thymic epithelial cell regeneration, restoring T-cell maturation and reversing immune system senescence.
Replaces & Revenue: Replaces experimental peptide protocols and intravenous immunoglobulin (IVIG) therapies. The IVIG market generates over $11 billion annually.

7. Chronic Cellular Inflammation (”Inflammaging”)

Gene Therapy Proposal: Systemic minicircle delivery of an engineered IL-10 or IL-1 Receptor Antagonist (IL-1Ra) variant with a constitutive promoter to maintain a youthful, balanced anti-inflammatory cytokine profile.
Replaces & Revenue: Replaces chronic NSAID use, corticosteroids, and off-label biologic use. The global anti-inflammatory biologics market exceeds $120 billion.

8. Telomere Attrition in High-Turnover Tissues

Gene Therapy Proposal: A transient, non-integrating minicircle vector encoding human Telomerase Reverse Transcriptase (hTERT) to safely extend telomeres in hematopoietic stem cells and dermal fibroblasts. Can an inducible construct create a solution without oncogenic risk?
Replaces & Revenue: Replaces unverified nutraceutical telomerase activators and high-end wellness supplements, capturing a multi-million dollar direct-to-consumer longevity market.

9. Osteoarthritis & Articular Cartilage Degradation

Gene Therapy Proposal: Intra-articular injection of a minicircle vector encoding Transforming Growth Factor-beta (TGF-beta) or IL-1Ra directly into the joint space to arrest cartilage catabolism and stimulate chondrocyte repair.
Replaces & Revenue: Replaces recurring hyaluronic acid injections, corticosteroid shots, and total joint replacements. Joint replacement surgeries represent a $20 billion global footprint.

10. Cognitive Decline & Synaptic Loss

Gene Therapy Proposal: Intrathecal or intranasal AAV-mediated delivery of Brain-Derived Neurotrophic Factor (BDNF) or Nerve Growth Factor (NGF) to preserve neuronal plasticity, protect dendritic spine density, and slow age-related memory deterioration.
Replaces & Revenue: Replaces cholinesterase inhibitors and off-label nootropics. The global dementia treatment market represents over $17 billion annually.

11. Hypercholesterolemia & LDL Accumulation

Gene Therapy Proposal: Hepatic delivery of a CRISPR-Cas9 or base-editing minicircle construct targeting and silencing the PCSK9 gene to permanently upregulate LDL receptor availability on hepatocytes.
Replaces & Revenue: Replaces monthly PCSK9 inhibitor monoclonal antibodies (e.g., Repatha) and daily statins. Repatha alone generates over $1.6 billion annually.

12. Hypertriglyceridemia & Cardiovascular Risk

Gene Therapy Proposal: AAV or minicircle delivery targeting the liver to overexpress Lipoprotein Lipase (LPL) or knock down Angiopoietin-like 3 (ANGPTL3), significantly lowering circulating very-low-density lipoproteins.
Replaces & Revenue: Replaces high-dose prescription omega-3 fatty acids and fibrates. The global lipid-lowering drug market generates over $20 billion annually.

13. Systemic Fibrosis (Liver, Kidney, and Heart)

Gene Therapy Proposal: Vector-mediated delivery of an engineered Decorin gene or matrix metalloproteinase (MMP-1/MMP-8) to actively degrade excess extracellular matrix and halt fibrotic remodeling in chronic disease.
Replaces & Revenue: Replaces pirfenidone and nintedanib. The anti-fibrotic therapy market is currently valued at over $4.5 billion.

14. Mitochondrial Myopathy & Metabolic Inefficiency

Gene Therapy Proposal: Minicircle-mediated delivery of Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (PGC-1-alpha) to muscle tissue to stimulate mitochondrial biogenesis and enhance oxidative phosphorylation.
Replaces & Revenue: Replaces high-dose CoQ10, L-carnitine cocktails, and experimental metabolic orphan drugs.

15. Bone Density Loss (Osteopenia/Osteoporosis)

Gene Therapy Proposal: Systemic minicircle delivery encoding an osteoprotegerin (OPG) Fc-fusion protein to neutralize RANKL, mimicking the mechanism of denosumab to continuously inhibit bone resorption.
Replaces & Revenue: Replaces twice-yearly denosumab (Prolia) injections and daily bisphosphonates. Prolia generates over $4 billion annually.

16. Cellular Accumulation of Advanced Glycation End-products (AGEs)

Gene Therapy Proposal: Genetic delivery of a soluble variant of the Receptor for Advanced Glycation End-products (sRAGE) into circulation to act as a decoy receptor, neutralizing circulating AGEs and reducing vascular cross-linking.
Replaces & Revenue: Replaces various metabolic supplements and anti-glycation cosmetics; opens up a completely novel therapeutic vertical in preventative longevity medicine.

17. Hypochlorhydria & Digestive Decline

Gene Therapy Proposal: Localized delivery to gastric parietal cells encoding an optimized proton pump gene or gastrin receptor variant to restore optimal stomach acid pH and improve nutrient absorption in older adults..
Replaces & Revenue: Replaces chronic use of over-the-counter betaine HCl supplements and addresses the long-term side effects of widespread proton pump inhibitor (PPI) abuse.

18. Dermal Atrophy & Skin Elastin Loss

Gene Therapy Proposal: Subcutaneous injection of a minicircle vector encoding human Tropoelastin and Type I Collagen under a fibroblast-specific promoter to permanently restore skin elasticity and thickness.
Replaces & Revenue: Replaces repetitive hyaluronic acid dermal fillers, botulinum toxin injections, and high-end laser resurfacing. The aesthetic dermatology market is valued at over $15 billion.

19. Hepatic Steatosis (Fatty Liver Disease)

Gene Therapy Proposal: Liver-targeted delivery of a transgene encoding Fibroblast Growth Factor 21 (FGF21) to enhance hepatic fatty acid oxidation, reduce lipotoxicity, and reverse early-stage non-alcoholic steatohepatitis (NASH).
Replaces & Revenue: Replaces experimental metabolic drugs and complex lifestyle interventions. The NASH therapeutics market is projected to surpass $10 billion.

20. Chronic Fatigue Syndrome, Cellular Energy Deficits & So Much More

Gene Therapy Proposal: Minicircle vector delivery encoding an engineered human NNMT (Nicotinamide N-methyltransferase) inhibitor peptide or antisense sequence to preserve cellular SAM and NAD+ pools, maximizing ATP output. The massive fat loss from inhibiting NNMT alone could be enough to surpass GLP-1 products. RNA products to inhibit NNMT are already in phase 1. NNMT also has interesting uses in oncology. As a master switch, controlling this will likely involve tight and precise inducible switching. A fortune awaits the engineer that cracks this.
Replaces & Revenue: Replaces off-label stimulant prescriptions, adaptogens, and expensive chronic fatigue protocol supplements.

II. Chronic Medical Conditions & Autoimmune Disorders

21. Type 2 Diabetes (Insulin Resistance)

Gene Therapy Proposal: Skeletal muscle-targeted minicircle delivery of a modified, uniquely inducible GLUT4 transporter to enable insulin-independent glucose uptake into muscle tissue. The lethal hypoglycemic risks are real, but perhaps you have a solution?
Replaces & Revenue: Replaces daily metformin, SGLT2 inhibitors, and exogenous insulin regimens. The global diabetes care market generates over $65 billion annually.

22. Rheumatoid Arthritis (RA)

Gene Therapy Proposal: Intra-articular or systemic delivery of a minicircle vector encoding a high-affinity TNF-alpha decoy receptor (similar to etanercept) or a continuous IL-1 antagonist construct.
Replaces & Revenue: Replaces weekly anti-TNF injections like Humira and Enbrel. Humira historically peaked at over $20 billion in annual revenue before biosimilar entry.

Rheumatoid arthritis, Wikicommons

23. Psoriasis & Psoriatic Arthritis

Gene Therapy Proposal: Intradermal or systemic delivery of a genetic construct producing an anti-IL-23 or anti-IL-17 monoclonal antibody directly from the host’s muscle tissue.
Replaces & Revenue: Replaces regular injections of Skyrizi and Cosentyx. Skyrizi alone pulled in $11.7 billion in 2024 sales.

24. Crohn’s Disease & Ulcerative Colitis (IBD)

Gene Therapy Proposal: Targeted enteric delivery via specialized oral capsular vectors or localized injection of an IL-10 or anti-alpha4beta7 integrin expression cassette to suppress localized mucosal inflammation.
Replaces & Revenue: Replaces intravenous infusions of Entyvio, Stelara, and Remicade. Stelara generates over $10 billion annually.

25. Chronic Kidney Disease (CKD) Anemia

Gene Therapy Proposal: A hypoxia-inducible minicircle vector delivering the Erythropoietin (EPO) gene to skeletal muscle, ensuring that EPO is synthesized only when systemic oxygen levels drop below a healthy threshold. Also a nice little performance enhancer for athletes (though performance enhancement would be better with a small-molecule switch over a hypoxia-inducible one), but the polycythemia risk & hematocrit capping needs to be carefully managed.
Replaces & Revenue: Replaces regular injections of recombinant human erythropoietin (Epogen/Procrit). The global EPO market exceeds $8 billion annually.

26. Hypertension (Chronic High Blood Pressure)

Gene Therapy Proposal: Endothelial or hepatic gene delivery of human Atrial Natriuretic Peptide (ANP) or endothelial Nitric Oxide Synthase (eNOS) to maintain continuous, baseline vasodilation. ANP is probably better, but you need to figure out a way around the priapism and hypotension risks.
Replaces & Revenue: Replaces daily oral ACE inhibitors, ARBs, and calcium channel blockers. The global antihypertensive market is worth over $30 billion.

27. Gout & Hyperuricemia

Gene Therapy Proposal: Hepatic delivery of a functional Urate Oxidase (Uricase) gene variant, allowing humans to metabolize insoluble uric acid into highly soluble allantoin, preventing crystal deposition. Must include a C-terminal peroxisomal targeting signal (such as a PTS1 tripeptide sequence) to safely route the expressed protein into the peroxisomes. Hydrogen peroxide is not our friend.
Replaces & Revenue: Replaces daily oral allopurinol or painful, immunogenic Pegloticase (Krystexxa) infusions. Krystexxa generates over $1 billion annually.

28. Severe Asthma & Eosinophilic Airway Inflammation

Gene Therapy Proposal: Inhaled aerosolized or systemic delivery of an expression cassette encoding an anti-IL-5 or anti-IgE antibody segment to permanently blunt airway hypersensitivity.
Replaces & Revenue: Replaces regular biologic injections like Xolair and Nucala, alongside daily steroid inhalers. Xolair sales exceed $4 billion annually.

29. Systemic Lupus Erythematosus (SLE)

Gene Therapy Proposal: Vector-mediated delivery of a B-cell Activating Factor (BAFF) inhibitor or anti-CD20 single-chain variable fragment (scFv) to safely downregulate autoantibody production.
Replaces & Revenue: Replaces Benlysta infusions and toxic immunosuppressive drugs like mycophenolate mofetil. Benlysta generates over $1.3 billion annually.

30. Multiple Sclerosis (MS) Neuroinflammation

Gene Therapy Proposal: Central nervous system (intrathecal) delivery of a vector encoding Interleukin-4 (IL-4) or Interleukin-10 (IL-10) under an astrocyte-specific promoter to skew the microenvironment away from demyelinating auto-immunity.
Replaces & Revenue: Replaces Ocrevus infusions and interferon injections. Ocrevus generates over $6.5 billion in annual revenue.

31. Atherosclerosis (Arterial Plaque Build-up)

Gene Therapy Proposal: Hepatic or vascular delivery of Apolipoprotein A-1 Milano (ApoA-1M), facilitating ultra-efficient reverse cholesterol transport to rapidly shrink unstable arterial plaques.
Replaces & Revenue: No current direct pharmaceutical equivalent exists on the market; replaces lifetime statin maintenance and invasive coronary stenting procedures.

32. Atopic Dermatitis (Severe Eczema)

Gene Therapy Proposal: Subcutaneous or localized intradermal delivery of an expression construct for an anti-IL-4 receptor alpha monoclonal antibody (functional equivalent to dupilumab).
Replaces & Revenue: Replaces bi-weekly Dupixent injections. Dupixent generates over $11 billion in annual sales.

33. Chronic Insomnia & Circadian Dysregulation

Gene Therapy Proposal: Intranasal or targeted neural delivery of an orexin receptor antagonist peptide or an RNAi knockdown, a native circadian rhythm promoter (Bmal1 or Per2), and/or perhaps another construct utilizing a light-sensitive or time-inducible promoter switch to restore deep sleep architecture and regular wake cycles.
Replaces & Revenue: Replaces chronic use of addictive benzodiazepines, Z-drugs (ambien), and over-the-counter melatonin supplements.

34. Non-Alcoholic Cirrhosis & Hepatic Fibrosis

Gene Therapy Proposal: Hepatic targeting of a minicircle vector delivering human Hepatocyte Growth Factor (HGF) to promote parenchymal regeneration and halt progressive liver failure.
Replaces & Revenue: Replaces generic palliative management and liver transplantation listing. Liver transplants cost upwards of $800,000 per procedure.

35. Gastroesophageal Reflux Disease (GERD)

Gene Therapy Proposal: Localized delivery to the lower esophageal sphincter muscle encoding a gene to increase baseline muscle tone or tissue density, permanently preventing acid reflux mechanically.
Replaces & Revenue: Replaces lifetime reliance on daily Proton Pump Inhibitors (Nexium, Prilosec), which are associated with long-term bone density and nutritional deficits.

36. Chronic Migraine Headaches

Gene Therapy Proposal: Skeletal muscle or hepatic delivery of a vector encoding an anti-Calcitonin Gene-Related Peptide (CGRP) monoclonal antibody fragment for continuous, preventive neural desensitization.
Replaces & Revenue: Replaces monthly preventative injections like Aimovig, Emgality, or Ajovy. The preventative CGRP class accounts for over $3 billion annually.

37. Chronic Obstructive Pulmonary Disease (COPD) Emphysema

Gene Therapy Proposal: Inhaled delivery of a functional Alpha-1 Antitrypsin (AAT) gene cassette into alveolar macrophages or epithelial cells to arrest progressive tissue destruction by elastases.
Replaces & Revenue: Replaces weekly, highly expensive intravenous AAT augmentation therapies (e.g., Aralast, Prolastin), which cost up to $100,000 per patient annually.

38. Celiac Disease & Gluten Autoimmunity

Gene Therapy Proposal: Hepatic or intestinal mucosal delivery of an immunodominant gluten peptide sequence engineered to induce peripheral immune tolerance through regulatory T-cell induction.
Replaces & Revenue: Replaces strict lifelong gluten-free dietary restrictions and experimental enzyme supplement therapies.

39. Chronic Pain & Neuropathic Hyperalgesia

Gene Therapy Proposal: Intrathecal or dorsal root ganglion delivery of a vector encoding human Preproenkephalin or an engineered Nav1.7 sodium channel blocker peptide to continuously suppress chronic pain signals at the spinal level.
Replaces & Revenue: Replaces addictive opioid prescriptions, gabapentinoids, and invasive spinal cord stimulator implants. The global chronic pain market exceeds $70 billion.

40. Benign Prostatic Hyperplasia (BPH)

Gene Therapy Proposal: Intraprostatic delivery of an inducible 5-alpha reductase type 2 antisense sequence or a localized pro-apoptotic peptide to reduce prostate volume and relieve urinary obstruction.
Replaces & Revenue: Replaces daily oral finasteride/tamsulosin cocktails and invasive transurethral resection (TURP) surgeries.

By Unknown author - National Cancer Institute, AV Number: CDR462221, Public Domain, https://commons.wikimedia.org/w/index.php?curid=5581217

III. Peptide Replacements & Endocrine Optimization

41. Chronic Growth Hormone Deficiency & Lean Mass Loss

Gene Therapy Proposal: An inducible minicircle vector delivering Growth Hormone Releasing Hormone (GHRH) or Growth Hormone (GH) controlled by a secure oral small-molecule switch.
Replaces & Revenue: Replaces expensive, daily subcutaneous recombinant human growth hormone injections.

42. Obesity & Chronic Appetite Suppression

Gene Therapy Proposal: Hepatic or muscle delivery of a long-acting, optimized GLP-1/GIP co-agonist peptide sequence for continuous, single-injection weight management and blood sugar stabilization. I mean, as long as it has a kill switch, it’s a better option than weekly injections for a medication that doctors are currently recommending for lifelong use. Watch out for permanent gastroparesis.
Replaces & Revenue: Replaces weekly injections of blockbuster medications like Ozempic, Wegovy, Mounjaro, and Zepbound. The combined market for these therapies reached $36.5 billion for Eli Lilly alone in 2025.

43. Secondary Hypogonadism & Low Testosterone

Gene Therapy Proposal: Muscular delivery of a genetic sequence encoding Kisspeptin-10 or Gonadotropin-Releasing Hormone (GnRH) under a pulse-mimicking promoter to restore natural, endogenous luteinizing hormone and testosterone production.
Replaces & Revenue: Replaces lifetime exogenous testosterone injections, gels, and pellets, bypassing the side effect of testicular atrophy. The global TRT market exceeds $4 billion.

44. Central Diabetes Insipidus

Gene Therapy Proposal: Long-term intramuscular minicircle delivery of a modified Arginine Vasopressin (AVP) transgene to restore systemic fluid regulation and stop chronic polyuria.
Replaces & Revenue: Replaces daily desmopressin nasal sprays or oral tablets.

45. Primary Adrenal Insufficiency (Addison’s Disease)

Gene Therapy Proposal: An ACTH-responsive, multi-cistronic vector system delivered to the adrenal cortex or an engineered subcutaneous cellular depot containing the steroidogenic enzymes necessary to restore physiologic cortisol synthesis.
Replaces & Revenue: Replaces lifetime oral hydrocortisone and fludrocortisone replacement therapy.

46. Post-Menopausal Osteoporosis & Vasomotor Symptoms

Gene Therapy Proposal: A liver-targeted or muscle-targeted delivery platform utilizing a weak estrogen-receptor alpha agonist peptide construct to safely maintain bone density and prevent hot flashes without stimulating breast or uterine tissue proliferation.
Replaces & Revenue: Replaces conventional hormone replacement therapy (HRT) and denosumab injections.

47. Hypoparathyroidism

Gene Therapy Proposal: Continuous muscular or subcutaneous tissue production of full-length human Parathyroid Hormone (PTH 1-84) via minicircle DNA to maintain normal calcium homeostasis without daily injections.
Replaces & Revenue: Replaces daily subcutaneous Natpara or high-dose calcium/calcitriol regimens. Natpara historically cost over $100,000 annually.

48. Severe Leptin Deficiency & Congenital Morbid Obesity

Gene Therapy Proposal: Systemic delivery of a human Leptin gene cassette to adipose or muscle tissue, restoring central satiety signaling and normalizing metabolic rate.
Replaces & Revenue: Replaces daily subcutaneous metreleptin (Myalept) injections, which cost upwards of $500,000 per year per patient. So yeah, this one has the potential for nice margins.

49. Chronic Hypoglycemia & Glycogen Storage Disease

Gene Therapy Proposal: A glucose-sensitive minicircle vector encoding human Glucagon, engineered to express and secrete only when blood glucose levels fall below 70 mg/dL.
Replaces & Revenue: Replaces emergency glucagon rescue kits and round-the-clock dietary cornstarch regimens.

50. Erectile Dysfunction (ED) & Nitric Oxide Insufficiency

Gene Therapy Proposal: Intracavernosal pelvic delivery of a minicircle vector encoding human Endothelial Nitric Oxide Synthase (eNOS) to permanently restore localized vascular responsiveness and erectile capacity. Another novel idea might be the use of an optogenetic switch coupled with tiny, injectable, passively powered NIR LEDs for instant erectile control, bypassing refractory periods at the push of a button. These injectable implants are already manufactured, so that is less on your plate. It crosses into the medical device realm in most jurisdictions, but not in Próspera!
Replaces & Revenue: Replaces oral PDE5 inhibitors like Viagra and Cialis or painful alprostadil penile injections. The global ED drug market exceeds $4.5 billion.

51. Muscle Atrophy via Anabolic Resistance

Gene Therapy Proposal: Continuous systemic secretion of a high-potency, stable Mechano-Growth Factor (MGF) peptide variant to bypass age-related anabolic blunting and accelerate injury recovery.
Replaces & Revenue: Replaces off-label body-building peptides (BPC-157, TB-500) and underground anabolic androgenic steroid use.

52. Chronic Anorexia Cachexia (Cancer/HIV Induced)

Gene Therapy Proposal: Muscle delivery of a genetic construct producing Ghrelin or a high-affinity Ghrelin receptor agonist to continuously stimulate appetite and preserve lean mass during wasting states.
Replaces & Revenue: Replaces synthetic cannabinoids, megestrol acetate, and intravenous nutritional formulas.

53. Sleep Apnea & Upper Airway Muscle Laxity

Gene Therapy Proposal: Localized delivery to the hypoglossal nerve and surrounding musculature encoding a neurotrophic factor or muscle-stabilizing peptide to enhance baseline muscle tone during sleep.
Replaces & Revenue: Replaces cumbersome CPAP machines and invasive surgical airway reconstructions. The global CPAP market exceeds $4 billion.

54. Anemia of Chronic Disease (ACD)

Gene Therapy Proposal: Systemic or hepatic delivery of a vector encoding an antisense sequence against Hepcidin or an engineered Ferroportin stabilizer to unlock trapped intracellular iron stores and normalize hemoglobin synthesis.
Replaces & Revenue: Replaces repetitive intravenous iron infusions and expensive erythropoietin-stimulating agents.

55. Hypothyroidism (Refractory Levothyroxine Malabsorption)

Gene Therapy Proposal: Intramuscular or subcutaneous delivery of a multi-cistronic construct containing thyroid peroxidase and thyroglobulin elements to establish a functional, hormone-producing thyroid micro-tissue depot. This also assumes you have the entire machinery setup: NIS for basal uptake, Pendrin for apical transport, and a hydrogen peroxide generation system (such as DUOX2 and DUOXA2) to drive the TPO-mediated iodination of thyroglobulin. Furthermore, without an organized follicular architecture to store colloid, the system isn’t going to function autonomously. Infinitia believes in you!
Replaces & Revenue: Replaces daily lifelong oral levothyroxine (Synthroid), one of the most widely prescribed drugs in the world.

56. Age-Related Dehydroepiandrosterone (DHEA) Decline

Gene Therapy Proposal: Adipose or muscle-targeted delivery of a transgene encoding the rate-limiting steroidogenic enzyme CYP17A1 to boost endogenous DHEA production back to peak youthful levels.
Replaces & Revenue: Replaces over-the-counter oral DHEA supplementation and anti-aging compound therapies.

57. Short Bowel Syndrome & Malabsorption

Gene Therapy Proposal: Intestinal or intramuscular production of a long-acting Teduglutide (GLP-2 analog) sequence via minicircle DNA to promote mucosal hypertrophy and structural adaptation of the remaining gut tissue.
Replaces & Revenue: Replaces daily subcutaneous Gattex injections, which cost over $400,000 annually per patient.

58. Refractory Vitamin D-Dependent Rickets

Gene Therapy Proposal: Hepatic delivery of a functional 25-Hydroxyvitamin D3 1-Alpha-Hydroxylase gene to permanently restore endogenous synthesis of active Calcitriol.
Replaces & Revenue: Replaces high-dose lifelong active vitamin D metabolite supplementation and frequent monitoring protocols.

59. Idiopathic Short Stature

Gene Therapy Proposal: Growth plate-targeted delivery of an Insulin-like Growth Factor 1 (IGF-1) construct under a highly localized, self-limiting developmental promoter to optimize long bone growth in pediatric patients.
Replaces & Revenue: Replaces daily recombinant hGH or Increlex injections, costing up to $60,000 annually.

60. Severe Exocrine Pancreatic Insufficiency

Gene Therapy Proposal: Duct-targeted or local parenchymal delivery of pancreatic lipase, amylase, and protease genes into the upper intestinal tissue, transforming mucosal cells into functional digestive enzyme producers.
Replaces & Revenue: Replaces the need to take dozens of daily oral porcine pancreatic enzyme replacement therapy (PERT) capsules (Creon) with every meal. Creon generates over $1.2 billion annually.

IV. Monoclonal Antibody Substitutes (In Vivo Bioreactors)

Note: All of these (and others in the list) assume an engineered immune tolerance and mitigation of anti-drug antibodies (ADAs).

61. Advanced Colorectal and Lung Cancer (VEGF Inhibition)

Gene Therapy Proposal: Muscle delivery of a minicircle vector encoding a soluble VEGF trap or a full anti-VEGF single-chain antibody variant (scFv) to maintain a constant anti-angiogenic barrier around solid tumors.
Replaces & Revenue: Replaces monthly intravenous infusions of Bevacizumab (Avastin). Avastin historically generated over $7 billion annually.

62. Advanced Melanoma, NSCLC, and Renal Carcinoma (PD-1 Blockade)

Gene Therapy Proposal: Intramuscular or peritumoral delivery of an expression construct producing an anti-PD-1 monoclonal antibody fragment to provide sustained, baseline checkpoint inhibition.
Replaces & Revenue: Replaces recurring Keytruda or Opdivo infusions. Keytruda is the world’s best-selling drug, generating over $29.5 billion in 2024 alone.

63. Her2-Positive Breast Cancer

Gene Therapy Proposal: Long-term skeletal muscle secretion of a full-length anti-HER2 monoclonal antibody sequence, maintaining therapeutic serum levels to neutralize circulating tumor cells and micro-metastases.
Replaces & Revenue: Replaces regular intravenous infusions of Herceptin (Trastuzumab). Herceptin historically generated over $6 billion in peak annual sales.

64. Severe Asthmatic Hypereosinophilia (IL-5 Inhibition)

Gene Therapy Proposal: A minicircle DNA vector delivered intramuscularly to continuously secrete an anti-IL-5 antibody fragment, blunting eosinophil activation and preventing severe airway constriction.
Replaces & Revenue: Replaces regular subcutaneous injections of Nucala (Mepolizumab). Nucala generates over $1.8 billion annually.

65. Wet Age-Related Macular Degeneration (AMD)

Gene Therapy Proposal: A single intraocular (intravitreal) injection of an AAV or minicircle vector encoding an anti-VEGF scFv, transforming retinal pigmented epithelial cells into factory lines for anti-VEGF production.
Replaces & Revenue: Replaces painful, recurring monthly eye injections of Eylea or Lucentis. Eylea generates over $9 billion globally per year.

66. Severe Hypercholesterolemia (PCSK9 Monoclonal Equivalent)

Gene Therapy Proposal: Sustained muscle production of an anti-PCSK9 single-chain variable fragment (scFv) to block circulating PCSK9 and maximize hepatic LDL clearance without requiring gene editing.
Replaces & Revenue: Replaces monthly Repatha or Praluent monoclonal antibody injections.

67. Osteoporosis (Sclerostin Inhibition)

Gene Therapy Proposal: Long-term vector production of an anti-Sclerostin monoclonal antibody fragment, mimicking the action of romosozumab to decouple bone formation and resorption for rapid skeleton reconstruction.
Replaces & Revenue: Replaces monthly subcutaneous injections of Evenity, which costs roughly $2,000 per month.

68. Advanced Bladder and Urothelial Carcinoma (PD-L1 Inhibition)

Gene Therapy Proposal: Muscular or regional peritumoral production of an anti-PD-L1 single-chain antibody, keeping immune checkpoints open to allow local T-cell clearance of malignant cells.
Replaces & Revenue: Replaces regular intravenous infusions of Tecentriq, which generates over $2.5 billion annually.

69. Paroxysmal Nocturnal Hemoglobinuria (PNH) & Macular Degeneration (C5 Complement Inhibition)

Gene Therapy Proposal: Hepatic delivery of a genetic construct secreting a high-affinity anti-C5 complement monoclonal antibody or decoy molecule to protect red blood cells from intravascular hemolysis.
Replaces & Revenue: Replaces lifelong, ultra-expensive Soliris or Ultomiris infusions. Soliris costs up to $500,000 per patient annually and generates over $4 billion globally.

70. Moderate-to-Severe Hidradenitis Suppurativa & Crohn’s (IL-17/23 Inhibition)

Gene Therapy Proposal: Muscle-mediated minicircle delivery encoding an anti-IL-17 or anti-IL-23 antibody fragment to maintain strict, localized cutaneous or mucosal cytokine suppression.
Replaces & Revenue: Replaces bi-weekly injections of Cosentyx or Bimzelx. Cosentyx generates over $5 billion annually.

71. Recurrent Clostridioides difficile Infection (Toxin B Neutralization)

Gene Therapy Proposal: Expression of an anti-C. difficile Toxin B neutralizing monoclonal antibody fragment in the gut lumen (apically-secreting epithelial vectors or an engineered probiotic chassis?), providing long-term mucosal defense against recurrent toxic megacolon. Every nurse’s favorite infection, neutralized.
Replaces & Revenue: Replaces single-dose Bezlotoxumab (Zinplava) infusions, which cost over $4,000 per dose.

72. Severe Chronic Urticaria (Hives)

Gene Therapy Proposal: Intramuscular production of an anti-IgE monoclonal antibody snippet, mirroring omalizumab’s mechanism to prevent mast cell and basophil degranulation safely.
Replaces & Revenue: Replaces monthly Xolair injections for refractory dermatological patients.

Hives, photo by Dr. James Heilman

73. Prevention of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Gene Therapy Proposal: Intramuscular injection of a minicircle vector encoding an anti-RSV fusion protein monoclonal antibody (functional equivalent to palivizumab/nirsevimab) to maintain a persistent protective antibody titer through the winter season.
Replaces & Revenue: Replaces seasonal prophylactic monoclonal antibody injections (Synagis/Beyfortus). Beyfortus sales have cleared $1 billion seasonally.

74. Alzheimer’s Amyloid-Beta Clearance

Gene Therapy Proposal: Intrathecal or systemic delivery of an expression construct encoding an anti-amyloid beta monoclonal antibody fragment (similar to lecanemab or donanemab) with enhanced blood-brain barrier transport properties.
Replaces & Revenue: Replaces regular, side-effect-prone intravenous infusions of Leqembi or Kisunla, which generate billions while requiring intense institutional clinical infrastructure.

75. Advanced Head and Neck Squamous Cell Carcinoma (EGFR Blockade)

Gene Therapy Proposal: Intramuscular or localized delivery of an expression vector producing an anti-EGFR antibody snippet to starve epithelial tumors of essential replication signals.
Replaces & Revenue: Replaces intravenous infusions of Cetuximab (Erbitux). Erbitux generates over $1 billion annually.

76. Prevention of Migraine (Sustained CGRP Ligand Neutralization)

Gene Therapy Proposal: Continuous muscular production of an anti-CGRP ligand antibody fragment (functional analog to galcanezumab), removing the peak-and-trough efficacy degradation seen at the end of every month.
Replaces & Revenue: Replaces monthly Emgality or Ajovy self-injections.

77. Severe Allergic Keratoconjunctivitis & Dry Eye Syndrome

Gene Therapy Proposal: Salivary gland or subconjunctival delivery of an expression cassette producing a localized anti-ICAM-1 or anti-TNF single-chain fragment to protect the ocular surface without systemic immunosuppression.
Replaces & Revenue: Replaces daily lifitegrast (Xiidra) or cyclosporine (Restasis) eye drops. Restasis generates over $1 billion annually.

78. Lupus Nephritis (BLyS/APRIL Dual Inhibition)

Gene Therapy Proposal: Systemic minicircle-mediated secretion of a dual B-lymphocyte stimulator (BLyS) and APRIL antagonist fusion protein to protect renal tissue from autoantibody attack.
Replaces & Revenue: Replaces recurring infusions of Benlysta or experimental dual-inhibitor biologics.

79. Systemic Amyloidosis Light Chain (AL) Disease

Gene Therapy Proposal: Intramuscular production of an amyloid-clearing monoclonal antibody fragment designed to bind to and degrade misfolded light-chain aggregates in organs.
Replaces & Revenue: Replaces aggressive chemo-immunotherapy combinations and experimental monoclonal therapies.

80. Refractory Eosinophilic Esophagitis

Gene Therapy Proposal: Local esophageal mucosal or intramuscular delivery of an anti-IL-13 single-chain antibody variant to eliminate painful fibrotic food impactions and strictures.
Replaces & Revenue: Replaces off-label swallowed steroid slurries and frequent Dupixent injections.

V. Neurological, Sensory, and Rare/Orphan Indications

81. Huntington’s Disease (HTT Triplet Repeat Knockdown)

Gene Therapy Proposal: Intrathecal AAV-mediated delivery of an artificial microRNA or antisense oligonucleotide construct targeting and silencing the mutant Huntingtin (mHTT) transcript within the striatum.
Replaces & Revenue: No disease-modifying therapies exist; replaces generic symptomatic treatment with vesicular monoamine transporter 2 (VMAT2) inhibitors like tetrabenazine.

82. Parkinson’s Disease (Dopamine Synthesis Restoration)

Gene Therapy Proposal: Striatal delivery of an AAV or minicircle construct expressing Aromatic L-Amino Acid Decarboxylase (AADC), transforming remaining striatal cells into highly efficient converters of levodopa into dopamine.
Replaces & Revenue: Replaces high-dose oral carbidopa/levodopa regimens, which cause severe motor fluctuations over time. The global Parkinson’s market exceeds $5 billion.

83. Amyotrophic Lateral Sclerosis (ALS - SOD1 Mutation)

Gene Therapy Proposal: Intrathecal delivery of a specialized siRNA or antisense construct designed to knock down expression of the toxic, misfolded Superoxide Dismutase 1 (SOD1) protein in spinal motor neurons.
Replaces & Revenue: Replaces Qalsody (tofersen) intrathecal injections and oral riluzole. Qalsody is priced at over $300,000 per year.

84. Spinal Muscular Atrophy (Adult-Onset/Milder Phenotypes)

Gene Therapy Proposal: Systemic or intrathecal delivery of a minicircle vector containing an antisense sequence designed to alter the splicing of the SMN2 gene, maximizing production of functional survival motor neuron protein.
Replaces & Revenue: Replaces multi-million dollar single-dose treatments like Zolgensma or recurring maintenance intrathecal injections of Spinraza. Spinraza pulls in more than $1.5 billion annually.

85. Alpha-1 Antitrypsin Deficiency Liver Pathogenesis

Gene Therapy Proposal: Hepatic delivery of a dual-action RNAi and gene replacement construct designed to knock down mutant Z-AAT protein accumulation while simultaneously expressing wild-type, functional AAT protein.
Replaces & Revenue: Replaces regular lifelong intravenous alpha-1 proteinase inhibitor infusions.

86. Leber Hereditary Optic Neuropathy (LHON - ND4 Mutation)

Gene Therapy Proposal: Intravitreal injection of an AAV vector containing a functional mitochondrial ND4 gene engineered for allotopic expression, directing the protein directly to retinal ganglion cell mitochondria.
Replaces & Revenue: No standard approved disease-modifying therapies are available in many Western markets; directly replaces supportive low-vision care.

87. Pompe Disease (Late-Onset Acid Maltase Deficiency)

Gene Therapy Proposal: Hepatic delivery of a minicircle vector encoding human Acid Alpha-Glucosidase (GAA), optimized for continuous high-level secretion into the bloodstream for widespread skeletal muscle uptake.
Replaces & Revenue: Replaces bi-weekly enzyme replacement therapy infusions (Lumizyme/Nexviazyme). Nexviazyme therapies cost hundreds of thousands of dollars annually per patient.

88. Fabry Disease (alpha-Galactosidase A Deficiency)

Gene Therapy Proposal: Liver-targeted delivery of a functional GLA gene cassette, transforming hepatocytes into a continuous, stable source of the alpha-galactosidase A enzyme to clear systemic globotriaosylceramine storage.
Replaces & Revenue: Replaces lifelong every-two-week infusions of Fabrazyme, which costs up to $300,000 per year.

89. Gaucher Disease Type 1 (Glucocerebrosidase Deficiency)

Gene Therapy Proposal: Hematopoietic stem cell or liver-directed delivery of the glucocerebrosidase (GBA) gene to permanently clear lipid accumulations in macrophages without regular medical monitoring.
Replaces & Revenue: Replaces regular lifelong enzyme replacement infusions like Cerezyme or substrate reduction capsules like Cerdelga. Cerezyme generates over $800 million annually.

90. Hereditary Angioedema (HAE - C1 Inhibitor Deficiency)

Gene Therapy Proposal: Hepatic or muscular production of a functional human C1 Esterase Inhibitor transgene via minicircle DNA to permanently prevent sudden, life-threatening vascular swelling events.
Replaces & Revenue: Replaces frequent prophylactic injections of Takhzyro or Cinryze. Takhzyro single-source revenue exceeds $1 billion annually.

91. Mucopolysaccharidosis Type I (Hurler/Scheie Syndrome)

Gene Therapy Proposal: Intrathecal or hepatic delivery of the alpha-L-iduronidase (IDUA) gene to continuously produce the enzyme necessary to clear toxic glycosaminoglycans throughout systemic tissues and the central nervous system.
Replaces & Revenue: Replaces weekly intravenous Aldurazyme infusions, which cost over $200,000 per year per patient.

92. Hemophilia A (Factor VIII Deficiency)

Gene Therapy Proposal: Hepatic delivery of an optimized B-domain deleted human Factor VIII gene cassette to restore continuous endogenous blood clotting capabilities.
Replaces & Revenue: Replaces frequent, emergency or prophylactic infusions of recombinant Factor VIII or Hemlibra. The clotting factor market represents a $10 billion annual global burden.

93. Hemophilia B (Factor IX Deficiency)

Gene Therapy Proposal: Liver-targeted delivery of the high-activity Factor IX Padua variant, requiring extremely low vector copy numbers to completely normalize blood clotting metrics.
Replaces & Revenue: Replaces regular Factor IX infusions and Hemgenix, a traditional gene therapy priced commercially at $3.5 million per dose.

94. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Lung Dysfunction

Gene Therapy Proposal: Repeated nebulized delivery of a non-integrating, lipid-nanoparticle encapsulated minicircle DNA vector containing the full-length CFTR gene to clear thick, static pulmonary mucus.
Replaces & Revenue: Replaces lifelong daily oral tri-potentiator pills like Trikafta. Trikafta generated over $9 billion in 2024 for Vertex Pharmaceuticals.

95. Wilson Disease (Copper Accumulation Disorder)

Gene Therapy Proposal: Hepatic delivery of a functional ATP7B copper transporter gene sequence to restore regular biliary copper excretion and protect patients from acute liver and neurological failure.
Replaces & Revenue: Replaces continuous, side-effect-heavy oral copper chelators (penicillamine) and strict zinc therapy regimens.

Prominent Kayser-Fleischer ring associated with Wilson Disease.

96. Duchenne Muscular Dystrophy (Becker-like Micro-dystrophin Conversion)

Gene Therapy Proposal: Systemic or high-dose muscle delivery of a highly functional micro-dystrophin gene under a muscle-specific creatine kinase promoter to halt progressive muscle necrosis. It’s systemic though, so targeted LNPs/VLPs all the way (spleen allowing), unless you have cracked a better solution? This is a legacy target in bioengineering, so a crown comes with the bag.
Replaces & Revenue: Replaces multi-million dollar traditional single-dose AAV alternatives (Elevidys) and chronic corticosteroid therapies.

97. Achromatopsia (CNGB3/CNGA3 Blindness)

Gene Therapy Proposal: Subretinal injection of an AAV vector delivering a functional copy of the CNGB3 or CNGA3 gene directly to cone photoreceptors, restoring daytime color vision and visual acuity.
Replaces & Revenue: No existing pharmaceutical options are available; directly replaces lifelong low-vision accommodation and occupational therapy infrastructure.

98. Chronic Tinnitus & Auditory Synaptic Loss

Gene Therapy Proposal: Localized inner-ear (intracochlear) delivery of Neurotrophin-3 (NT-3) or Atonal (ATOH1) expression constructs to stimulate spiral ganglion neuron neurite outgrowth and repair damaged auditory synapses.
Replaces & Revenue: Replaces ineffective sound-masking devices and white noise generators; opens a completely unaddressed multi-billion dollar audiology sector.

99. Severe Refractory Hyperoxaluria Type 1

Gene Therapy Proposal: Liver-targeted delivery of a functional alanine-glyoxylate aminotransferase (AGXT) gene or an RNAi construct targeting glycolate oxidase to completely stop the production of toxic, stone-forming oxalate.
Replaces & Revenue: Replaces continuous monthly Oxlumo subcutaneous injections, which cost upwards of $400,000 per year per patient.

100. Advanced Epithelial Ovarian Cancer (Folate Receptor Alpha Targeting)

Gene Therapy Proposal: Muscle or intraperitoneal delivery of a vector encoding an anti-Folate Receptor Alpha single-chain variable fragment (scFv) conjugated to a potent cytotoxic or immune-recruiting peptide to constantly target and eliminate ovarian tumor cell lines.
Replaces & Revenue: Replaces recurring intravenous infusions of Elahere, a newly approved antibody-drug conjugate generating hundreds of millions in early market adoption.

This list represents over $725 billion in annual healthcare spending that is just waiting to be disrupted. But this is just the tip of the iceberg, as hundreds or thousands of other targets exist.

In the right regulatory environments, biotech and biopharma are revealed to be absolute goldmines, as well as a noble quest to improve quality of life for people worldwide.

100 Gene Therapy Opportunities for Potential…